vimarsana.com

Latest Breaking News On - Aptose biosciences company profile - Page 1 : vimarsana.com

Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews com

Equities research analysts at StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO – Get Free Report) (TSE:APS) in a note issued to investors on Wednesday. The brokerage set a “hold” rating on the biotechnology company’s stock. Several other analysts also recently commented on APTO. HC Wainwright reaffirmed a “buy” rating and set a $23.00 […]

Aptose Biosciences (TSE:APS) Hits New 1-Year Low at $1 36

Aptose Biosciences (TSE:APS) Hits New 1-Year Low at $1 36
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

Aptose Biosciences (NASDAQ:APTO) Now Covered by Analysts at StockNews com

Investment analysts at StockNews.com initiated coverage on shares of Aptose Biosciences (NASDAQ:APTO – Get Free Report) (TSE:APS) in a report released on Wednesday. The firm set a “hold” rating on the biotechnology company’s stock. Other analysts also recently issued research reports about the company. Piper Sandler reaffirmed an “overweight” rating and issued a $5.00 price […]

Aptose Biosciences (NASDAQ:APTO) Price Target Lowered to $6 00 at Canaccord Genuity Group

Aptose Biosciences (NASDAQ:APTO – Get Free Report) (TSE:APS) had its target price cut by Canaccord Genuity Group from $15.00 to $6.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity Group’s target price would suggest a potential upside of […]

Canaccord Genuity Group Trims Aptose Biosciences (NASDAQ:APTO) Target Price to $6 00

Aptose Biosciences (NASDAQ:APTO – Get Free Report) (TSE:APS) had its price target dropped by equities researchers at Canaccord Genuity Group from $15.00 to $6.00 in a report released on Thursday, Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity Group’s price target would indicate a potential upside of […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.